[New therapeutic approach to pancreatic cancer by monoclonal antibodies].
The prognosis of pancreatic cancer is extremely poor in digestive cancers even with systemic therapy including surgery. Thus development of a new therapeutic approach is awaited. Recently, new trials of cancer treatments using monoclonal antibodies conjugated with anti-cancer drugs or labeled with isotopes have been reported. Here, we discuss the possible therapeutic application for pancreatic cancer of adriamycin-conjugated and 131I-labeled Nd2, which is produced against pancreatic cancer mucin.
Sawada
T
T
First Dept. of Surgery, Osaka City University Medical School, Osaka, Japan.
Chung
Y S
YS
Sowa
M
M
D000818:Animals; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D004317:Doxorubicin / Q000627:therapeutic use; D006801:Humans; D000922:Immunotoxins / Q000627:therapeutic use; D007554:Isotopes; D051379:Mice; D008819:Mice, Nude; D009354:Neodymium / Q000627:therapeutic use*; D010190:Pancreatic Neoplasms / Q000532:radiotherapy*; D016499:Radioimmunotherapy
D000911:Antibodies, Monoclonal; D000922:Immunotoxins; D007554:Isotopes; D009354:Neodymium; D004317:Doxorubicin